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The life expectancy for pancreatic cancer patients has seen no substantial changes in the last 
40 years as very few and mostly just palliative treatments are available. As the five years 
survival rate remains around 5% the identification of novel pharmacological targets and 
development of new therapeutic strategies are urgently needed. Here we demonstrate that 
inhibition of the G protein-coupled receptor GPR55, using genetic and pharmacological 
approaches, reduces pancreatic cancer cell growth in vitro and in vivo and we propose that 
this may represent a novel strategy to inhibit pancreatic ductal adenocarcinoma (PDAC) 
progression. Specifically, we show that genetic ablation of Gpr55 in the 
KRASWT/G12D/TP53WT/R172H/Pdx1-Cre+/+ (KPC) mouse model of PDAC significantly prolonged 
survival. Importantly, KPC mice treated with a combination of the GPR55 antagonist 
Cannabidiol (CBD) and gemcitabine (GEM, one of the most used drugs to treat PDAC), 
survived nearly three times longer compared to mice treated with vehicle or GEM alone. 
Mechanistically, knockdown or pharmacologic inhibition of GPR55 reduced anchorage 
dependent and independent growth, cell cycle progression, activation of mitogen-activated 
protein kinase (MAPK) signalling and protein levels of ribonucleotide reductases in PDAC 
cells. Consistent with this, genetic ablation of Gpr55 reduced proliferation of tumour cells, 
MAPK signalling and ribonucleotide reductase M1 levels in KPC mice. Combination of CBD 
and GEM inhibited tumour cell proliferation in KPC mice and it opposed mechanisms involved 
in development of resistance to GEM in vitro and in vivo. Finally, we demonstrate that the 
tumour suppressor p53 regulates GPR55 protein expression through modulation of the 
microRNA miR34b-3p. Our results demonstrate the important role played by GPR55 
downstream of p53 in PDAC progression. Moreover our data indicate that combination of CBD 
and GEM, both currently approved for medical use, might be tested in clinical trials as a novel 
promising treatment to improve PDAC patients’ outcome. 
 




The progression from normal duct epithelium to infiltrating pancreatic ductal adenocarcinoma 
(PDAC) involves development of a characteristic pattern of precursors named pancreatic 
intraepithelial neoplasias (PanIN), histologically classified into distinct stages (PanIN 1a, 
PanIN 1b, PanIN 2, and PanIN 3) which eventually develop into PDAC, further classified in 
five distinct stages.1 The genetic alterations associated with this process have been 
extensively characterised and they involve activating mutations of oncogenes, inactivating 
mutations of tumour suppressors as well as increased copy numbers of receptors.2 For 
instance it is now well established that activating mutations of the oncogene KRas occur early 
during PanINs development and are detected in 85-90% of PDAC tumours.3 On the other 
hand inactivating mutations of the tumour suppressor TP53 occur in 70% of the latest stages 
of PanIN progression.4 Transgenic mouse models have shed much light into the role of these 
specific mutations during PDAC development. The KRASWT/G12D/Pdx1-Cre+/+  (KC) model 
which expresses a constitutively active KRas selectively in the pancreas is able to reproduce 
the PanIN lineage with a 100% penetrance but only few mice actually develop PDAC.5 On the 
contrary the transgenic KRASWT/G12D/TP53WT/R172H/Pdx1-Cre+/+ (KPC) mice which additionally 
bear the TP53 inactivating mutation develop the full PanIN range and PDAC with pathology 
very similar to human PDAC.6 Therefore these transgenic models point to a key role for 
activated KRas in the early stage of neoplasias/cancer development and a central role for 
loss/inactivation of p53 in driving progression from the final PanINs stages to full PDAC.  
In the last years our understanding of the genetic causes of PDAC has greatly 
increased but sadly this has not resulted in significant improvement of treatment options for 
patients. Surgical resection can lead to long-term survival and provides effective palliation but 
it is only applicable to patients with stage I and II PDAC. Chemotherapy and radiation therapy 
following the resection reduce metastatic development but these treatments result in little 
improvement of patient survival. Until very recently, Gemcitabine (GEM) was the only FDA-
approved treatment for primary PDAC, but in most cases it can only prolong survival by several 
weeks.7 Some combinations of drugs have proven slightly more successful although they still 
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effectively increase patients’ survival by merely 2-4 months compared to GEM treatment.8, 9 
Several clinical trials are ongoing but currently PDAC remains one of the most aggressive 
cancers with a one year survival rate of 19% and five years survival rate of 5%.10 Identification 
of novel pharmacological targets and development of new therapeutic strategies are urgently 
needed.11  
Here we investigated the therapeutic potential of targeting the G protein-coupled 
receptor GPR55 in PDAC. GPR55 was identified as the receptor for the phospholipid 
lysophosphatidylinositol (LPI).12 Increasing evidence now suggests that GPR55 plays an 
important role in many cancer types.11 Whether targeting the receptor could ultimately result 
in improvement of survival and whether this strategy could represent a genuine novel 
therapeutic approach remains to be determined. Indeed, no study so far has investigated 
whether inhibition of GPR55 could improve survival of transgenic models that closely mirror 
the human disease.  
Using genetic and pharmacological approaches we demonstrate that GPR55 has a 
central role in PDAC progression driven by TP53 mutations. Furthermore, we show that 
inhibition of this receptor, especially in combination with GEM, reduces cancer progression 
and significantly improves survival in a transgenic mouse model of PDAC. These data provide 
the first evidence that inhibition of GPR55 represents a novel therapeutic strategy which can 





Genetic disruption of Gpr55 inhibits pancreatic cancer proliferation in vivo and it improves 
survival in a PDAC mouse model  
Immunohistochemistry (IHC) analysis of human normal pancreatic and PDAC specimens 
showed that GPR55 immunoreactivity was confined to the islets of Langerhans (Figure 1a) in 
normal pancreatic tissues, as previously reported,13 while acinar cells and ducts were 
consistently negative (Figure 1a). On the other hand, GPR55 was expressed in 14 out of 54 
human PDAC specimens (25.9%), indicating an accumulation of GPR55 in cancer tissues. 
Consistently, GPR55 was detected in PDAC specimens derived from implantation of patient-
derived pancreatic cancer cells (patient-derived xenografts, PDX, Figure 1a) and in a panel of 
PDAC cell lines (Supplementary Figure 1a). 
To determine the role of GPR55 in PDAC, KPC mice were crossed with mice 
harbouring homozygous deletion of Gpr55 (GPR55-/-)14 to obtain the “KPCG” strain. Consistent 
with results from human tissues, IHC analysis indicated that GPR55 was specifically 
expressed by cells of the islets of Langerhans in Pdx1-Cre+/+ and KPC mice, but not in KPCG 
mice (Supplementary Figure 1b). Moreover, expression of GPR55 was detected in PDAC cells 
from KPC but not KPCG mice (Supplementary Figure 1b), confirming the specificity of the anti-
GPR55 antibody. Strikingly, genetic disruption of Gpr55 significantly improved survival (Figure 
1b). Specifically, the median survival was 32.5 days longer in KPCG mice (n=18) than in KPC 
mice (n=21). IHC analysis of corresponding dissected tumours indicated that GPR55 
disruption reduced expression of the proliferative index Ki67 in the epithelial cells, specifically 
during the PanIN 2 and PanIN 3 progression stages (Figure 1c), indicating a role for GPR55 
in pancreatic cancer cell proliferation. 
These data demonstrate that GPR55 is crucial for PDAC development and/or 
progression in vivo.  
 
GPR55 regulates cell cycle progression and MAPK signalling pathway.  
6 
 
Consistent with the in vivo data, siRNAs-mediated downregulation of GPR55 in PDAC cell 
lines significantly reduced cell proliferation (Supplementary Figures 2a and c and e) and 
anchorage-independent growth (Figures 2a and b). Efficient downregulation of GPR55 was 
confirmed by RT-qPCR (Supplementary Figures 2b and d and f). The inhibition of cell growth 
was mainly due to an effect on cell cycle progression as GPR55 downregulation significantly 
blocked the cell cycle at the G1/S transition phase (Supplementary Figures 3a and b) and 
reduced the mRNA levels of cyclins involved in regulation of the G1/S transition phase 
(including cyclin D1 and cyclin D2) without affecting mRNA levels of cyclin B1, which is 
involved in the G2/M transition (Supplementary Figure 3c). No increase in apoptosis was 
detected in PDAC cells upon GPR55 downregulation as assessed by Caspase 3 activity 
(Supplementary Figure 3d) or Annexin V/FACS (Supplementary Figure 3e) assays. These 
data demonstrate that GPR55 plays a specific role in PDAC cell proliferation/growth. 
To further investigate the mechanism involved in cell growth and cell cycle regulation, 
the signalling pathways downstream of GPR55 were investigated in PDAC cells. As shown in 
Supplementary Figure 3f, phosphorylation of ERK1/2 at residues Threonine 202 and Tyrosine 
204 was reduced in HPAFII cells transiently transfected with specific siRNAs targeting GPR55 
compared to cells transfected with a non-targeting siRNA (“siControl”) or incubated with 
transfection reagent alone (“untreated”). GPR55 downregulation further inhibited 
phosphorylation of S6 at its residues Serine 235/236 (Supplementary Figure 3f), which can be 
regulated downstream of the MAPK/ERK signalling pathway.15 Efficient downregulation of 
GPR55 was confirmed by Western blot (Supplementary Figure 3f). No effect on the total levels 
of ERK and S6 was detected upon downregulation of GPR55 (Supplementary Figure 3f). 
Consistently, IHC analysis revealed a decrease in both ERK1/2 and S6 phosphorylation in 
tumour specimens from KPCG mice compared to KPC mice (Figure 2c and d).  
These data indicate that one of the mechanisms by which GPR55 controls pancreatic 
cancer cell growth may be through regulation of the MAPK/ERK signalling pathway.  
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p53 regulates GPR55 protein expression through modulation of miR34b-3p levels.  
To assess further the specific role of GPR55 during PDAC development/progression we 
crossed GPR55-/- mice with KC mice, which do not harbor the TP53 mutation. No statistical 
differences were found in the survival of KC (n=19) compared to Gpr55-/-/KRASWT/G12D/Pdx1-
Cre+/+ (KCG, n=12) mice, suggesting a role for the tumour suppressor p53 in the regulation of 
GPR55. To investigate this hypothesis, GPR55 protein expression was analysed in murine 
PDAC cell lines established from different transgenic mouse models. Results in 
Supplementary Figure 4a suggest that GPR55 protein expression is negatively associated 
with TP53 status, as the protein appears to be less expressed in the presence of wild type 
TP53 (PZR1 cells, derived from the KC model), whereas it is more expressed when TP53 is 
mutated (PZPR1 cells, derived from the KPC model) or deleted (PZPflR cells). Furthermore, 
overexpression of wild type p53 in ASPC1 cells (that harbour a TP53 mutation) reduced the 
expression levels of GPR55 compared to cells transfected with the empty vector 
(Supplementary Figure 4b). On the other hand downregulation of p53 with two specific siRNAs 
strongly increased the expression levels of GPR55 in pancreatic cancer cells SW1990 that 
express wild type p53 (Figure 3b) and in HEK293T cells (Supplementary Figure 4c). These 
data indicate that wild type p53 negatively regulates GPR55 protein levels.  
To gain further insight into the mechanisms of the p53-dependent regulation of GPR55, 
we performed luciferase assays using a plasmid containing the luciferase gene under the 
control of the 3’-untranslated region (3’-UTR) of GPR55 (“GPR55” in Figure 3c). A plasmid 
encoding the luciferase gene but lacking a regulatory region was used as a control (“Control” 
in Figure 3c). ASPC1 cells were co-transfected with each luciferase plasmid in combination 
with either an empty vector (pcDNA) or plasmids encoding wild type p53 or mutants p53 
(harboring mutations at positions 143Ala or 175His). Wild type and p53 mutants were expressed 
to similar levels in these experimental conditions (Supplementary Figure 4d). Results showed 
that the luciferase activity driven by 3’-UTR GPR55 was significantly decreased in cells 
expressing wild type p53 but not in cells expressing the mutant p53 (Figure 3c). These data 
demonstrate that wild type p53, but not its mutated forms, negatively affects GPR55 protein 
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expression by specifically regulating its 3'-UTR and influencing GPR55 mRNA degradation or 
translation. We next investigated whether the p53-dependent regulation of 3’-UTR GPR55 
occurred directly or indirectly, possibly through regulation of microRNAs (miRs). More than 
one algorithm predicted GPR55 as a target of several miRs belonging to the miR34 family 
(Supplementary Table 1), which is known to be regulated by p53,16 to be downregulated in 
PDAC and to have a key role in PDAC progression.17 Specifically, we observed that miR34b-
3p was the only miR within this family with a binding site on 3'-UTR GPR55 as predicted by 
MicroCosm (Supplementary Figure 4e), strongly suggesting that this specific miR could be 
involved in the p53-mediated regulation of GPR55 in PDAC cells. Consistent with this, we 
observed that miR34b-3p was downregulated in ASPC1 and HPAFII cells compared to the 
immortalised pancreatic cell line HPDE (Supplementary Figure 4f). Re-introduction of wild type 
p53 in ASPC1 cells increased miR34b-3p levels (Supplementary Figure 4g) while re-
introduction of miR34b-3p in HPAFII and ASPC1 cells decreased GPR55 protein expression 
(Figure 3d).  
These data indicate that wild type p53 downregulates GPR55 protein expression by 
modulating the levels of miR34b-3p (Figure 3e) and suggest a mechanism by which TP53 
mutations might promote cell growth through impaired regulation of miR34b-3p levels, which 
in turn results in increased expression of GPR55 and amplification of proliferative signals 
(Figure 3e).  
 
Pharmacological inhibition of GPR55 reduces PDAC cell growth, cell cycle progression and 
MAPK signalling in vitro.  
Our data so far demonstrated that pancreatic cancer cell proliferation in vitro and, importantly, 
PDAC progression in vivo could be inhibited by genetic Gpr55 disruption. To validate the 
possibility of targeting GPR55 as a novel potential strategy in PDAC, we next investigated the 
effect of its pharmacological inhibition in vitro and in vivo. The GPR55 antagonist cannabidiol 
(CBD) efficiently inhibited anchorage-dependent growth of ASPC1, HPAFII, BXPC3 and 
PANC1 (Supplementary Figure 5a-d) cells. Similar results were obtained using the GPR55 
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antagonist CID16020046 (CID) in ASPC1 and HPAFII (Supplementary Figure 5a and b) cells. 
Treatment of HPAFII (Figure 4a) and PANC1 (Figure 4b) cells with CBD blocked cell cycle at 
the G1/S transition phase in a dose-dependent manner and it reduced DNA synthesis/entry in 
the S phase, as assessed by EdU incorporation (Figure 4c). Consistent with this, CBD reduced 
expression of cyclin D1 and activation of the tumour suppressor retinoblastoma (RB) without 
affecting the total levels of RB (Figure 4d). Inhibition of MEK/ERK and ERK-dependent 
pathways was also observed in cells treated with CBD (Figure 4e). On the other hand, no 
effect was detected on the total levels of any of the analysed proteins (Figure 4e). To 
investigate further the effect of CBD on different cell signalling pathways, we performed a 
human phospho-kinase array assay on lysates from untreated and CBD-treated HPAFII cells. 
Consistent with our previous data, results from the array confirmed a specific inhibition of 
ERK1/2 phosphorylation (25% threshold) upon treatment with CBD (Supplementary Figure 6). 
Importantly, Stat5a was the only other kinase whose phosphorylation appeared to be reduced 
by CBD treatment (25% threshold), although further investigation of additional, independent 
lysates did not confirm the Stat5a phosphorylation inhibition. Overall data from the array ruled 
out the possibility that CBD, at the concentrations used in this study, had many off target 
inhibitory effects on additional signalling pathways involved in regulation of cell growth and 
cell cycle progression. Finally, we observed that both CBD and CID inhibited anchorage-
independent growth of ASPC1 and HPAFII cells (Figures 5a and b).  
These data indicate that pharmacological inhibition of GPR55 reduces PDAC cell cycle 
progression and cell growth, suggesting that GPR55 may represent a novel target to 
counteract PDAC progression. 
 
Pharmacological inhibition of GPR55 potentiates the effect of gemcitabine (GEM) in vivo and 
in vitro  
We then investigated the effect of CBD on PDAC progression in vivo either alone or in 
combination with GEM. KPC mice were given CBD (100mg/kg), GEM (100mg/kg) or a 
combination of the two drugs, and survival curves were determined (Figure 5c). Lifespan 
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of mice given CBD (mean 25.4 days, median 22 days) was very similar to survival of mice 
given GEM (mean 27.8 days, median 23.5 days). Survival of mice given the vehicle was: mean 
18.6 days, median 20 days. Strikingly, a remarkable and statistically significant increase in 
survival was observed when CBD was used in combination with GEM, with a nearly three-fold 
extension of mice survival compared to mice given the vehicle (mean 52.7 vs 18.6 days, 
median 56 vs 20 days). To determine the mechanism(s) underlying the pronounced effect of 
the drug combination on PDAC growth, we next analysed tumour specimens from the four 
groups of mice. IHC analysis indicated that combination of the two drugs strongly reduced the 
percentage of proliferative cells, as assessed by Ki67 staining (Figure 5d). Combination of 
CBD and GEM reduced the number of HPAFII (Supplementary Figure 7a) and PANC1 
(Supplementary Figure 7b) cells more efficiently than each compound alone, as further 
confirmed by analysis of combination (CI) and dose reduction (DRI) indexes18 using 
CompuSyn software (Supplementary Table 2). 
These data indicate that combination of CBD and GEM strongly inhibits PDAC growth 
in vitro and in vivo. 
 
Pharmacological inhibition of GPR55 affects signalling pathways involved in acquired 
resistance to GEM  
IHC investigation revealed reduced ERK phosphorylation in tumours from mice given CBD 
(Figure 6a). A trend towards inhibition of S6 phosphorylation was also observed, although data 
did not reach statistical significance (Figure 6b). We detected increased ERK activation in 
tumours from mice given GEM compared to mice given the vehicle (Figure 6a). Increased 
ERK activation was previously reported upon GEM treatment and it was proposed as one of 
the mechanisms of acquired resistance to GEM treatment.19 Importantly, IHC analysis of 
tumours from mice given a combination of CBD and GEM showed that CBD was able to 
counteract the effect of GEM on ERK and ultimately to reduce the GEM-dependent ERK 
phosphorylation (Figure 6a). Similarly, we observed that GEM increased ERK activation in 
HPAFII cells and this was opposed by CBD when the two drugs were used in combination 
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(Figure 6c). No effects were observed on ERK expression levels (Figure 6c). In the same 
experiments GEM induced phosphorylation of the histone variant H2AX (Figure 6c), a well-
known marker of DNA damage.  
Next, we investigated the effect of CBD on additional proposed mechanisms of GEM 
resistance. It was demonstrated that GEM can act by inhibiting the enzyme ribonucleotide 
reductase 1 (RRM1), leading to imbalance in the deoxyribonucleotides pool. Moreover, it was 
shown that cancer cell resistance can be associated with increased RRM1 and RRM2 
expression.20, 21 We observed that GPR55 downregulation reduced RRM1 protein expression 
in HPAFII cells (Figure 7a). Similarly, treatment with CBD reduced the levels of both RRM1 
and RRM2 (Figure 7b). Moreover, reduced expression of RRM1 was detected in tumour 
specimens from KPCG compared to KPC mice (Figure 7c). Reduced levels of RRM1 mRNA 
were also observed in HPAFII cells upon treatment with CBD (Supplementary Figure 8a) and 
in KPCG compared to KPC mice (Supplementary Figure 8b). These data led us to hypothesise 
that CBD could counteract potential resistance mechanisms associated with upregulation of 
ribonucleotide reductases. Supporting this hypothesis, we detected increased expression of 
RRM1 in tumours from KPC mice given GEM (Figure 7d). While CBD alone did not seem to 
affect RRM1 levels, it was able to oppose the increase of RRM1 expression induced by GEM 
when the two drugs were used in combination (Figure 7d).  
 
DISCUSSION 
GPR55 has recently emerged as a key player in many cellular functions associated with 
cancer progression.11 This role was initially suggested by the demonstration that GPR55 is 
the specific receptor for LPI12, 22 whose role in cancer has been extensively described.11, 23-25 
From our original studies reporting the mitogenic properties of LPI24, 26, data in literature have 
increasingly documented the involvement of LPI in several cellular processes required for 
cancer progression, including cancer cell proliferation, migration and angiogenesis.22, 27, 28 
Studies also demonstrated that Ras-transformed epithelial thyroid cells and fibroblasts24, 26 
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and different cancer cell lines22, 28 are able to release LPI and increased levels of this 
phospholipid were found in ovarian cancer29 and colon cancer30 patients. Data indicating a 
specific requirement for GPR55 in modulation of most of the detected LPI-dependent functions 
provided the first indication that the receptor might be involved in cancer progression. 
Subsequent evidence supported this conclusion, including data demonstrating that GPR55 
itself is overexpressed in many cancer cells22, 27, 31, 32 and that GPR55 mRNA levels increase 
in human skin, larynx and oral squamous cell carcinoma compared to healthy tissues.32 
Increased levels of GPR55 mRNA were also detected in highly aggressive breast tumours31 
and high expression of GPR55 was recently associated with basal/triple-negative breast 
cancer subtype.33 
A previous study reported increased levels of GPR55 mRNA in PanIN 2/3 compared 
to PanIN 1b.31 GPR55 mRNA was also detected in the PDAC cell lines Mia PaCa-231 and 
PANC1,34 the latter cells also expressing the receptor at the protein level.34 Apart from these 
preliminary observations, no study has investigated whether accumulation of GPR55 occurs 
in PDAC and whether the receptor plays a role during PDAC development and progression. 
In this study, we show for the first time that GPR55 accumulates in human PDAC specimens 
compared to corresponding ductal areas in normal pancreatic tissue and it is detectable at the 
protein levels in a panel of PDAC cell lines. We demonstrate that the tumour suppressor p53 
negatively regulates GPR55 protein expression in a mechanism involving regulation of 
miR34b-3p. As miR34b-3p itself was previously reported to be downregulated in PDAC and 
to have a key role in PDAC progression35 our data identify a novel p53/miR34b-3p/GPR55 
axis in this process.  
We further show that downregulation and pharmacological inhibition of GPR55 
reduced anchorage dependent and independent growth of PDAC cells, consistent with data 
previously indicating that GPR55 is an important regulator of cancer cell proliferation.11, 22 More 
importantly we report that genetic disruption of Gpr55 in KPC mice significantly reduced 
cancer cell proliferation in vivo, providing the first evidence that this receptor is important for 
pancreatic cancer proliferation in this established PDAC mouse model. Extensive in vitro 
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characterisation further demonstrated that growth inhibition was due to inhibition of cell cycle 
progression without increased apoptosis and it involved regulation of MAPK signalling 
pathways. Indication of a direct role of GPR55 in cancer progression was previously provided 
by the observation that GPR55-/- mice were more resistant to skin cancer development 
compared to wild type mice.32 Similarly, delivery of siRNA targeting GPR55 in xenografts of 
T98G glioma cells reduced tumour growth in vivo.31 Inhibition of metastasis formation was 
detected in mice injected with human colon cancer cells and treated with pharmacological 
inhibitors of GPR5530 and in mice injected with human breast cancer cells lacking GPR55.33 
Adding to these data, our study provides the first demonstration that disruption of Gpr55 can 
directly affect proliferation of the highly aggressive PDAC in the closest genetic model that is 
currently available to mimic the human disease and it can significantly extend the lifespan of 
KPC mice, providing the first evidence that targeting GPR55 can result in improvement of 
survival.  
Although previous studies had provided preliminary indication that targeting GPR55 
could potentially represent a novel therapeutic strategy in cancer31, 32 no study so far had 
investigated whether pharmacological inhibition of GPR55 could directly improve survival in a 
model of PDAC. As we observed that GPR55 downregulation inhibited proliferation without 
inducing apoptosis, we decided to determine the effect of the GPR55 antagonist CBD alone 
or in combination with GEM, a cytotoxic drug currently used for PDAC treatment. It is worth 
mentioning that, although CBD has been confirmed to be a GPR55 antagonist, we could not 
completely rule out the possibility of additional effects of the drug, independent of GPR55 
inhibition. However, the observation that similar data were obtained in vitro upon treatment 
with CBD or with the specific GPR55 antagonist CID as well as upon downregulation of GPR55 
strongly supported the conclusion that the reduced cell growth/cell cycle progression detected 
in PDAC cells upon treatment with CBD was mainly due to inhibition of GPR55. Furthermore, 
results from the phospho-kinase array assay indicated that CBD did not inhibit activation of 
many signalling pathways, ruling out the possibility that the compound, at the concentrations 
used in our study, had many off target effects. Finally, we decided to use CBD in the in vivo 
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experiments as this drug is already approved for medical use therefore results from our study 
could have an immediate potential translational value. Here we report that KPC mice given a 
combination of CBD and GEM survived nearly three times longer compared to KPC mice given 
the vehicle (mean 52.7 vs 18.6 days, median 56 vs 20 days) and also longer than mice given 
GEM alone (mean 52.7 vs 27.8 days, median 56 vs 23.5). Our data further indicate that the 
remarkable increase in survival is likely due to the ability of the drugs combination to inhibit 
cancer cell proliferation and to overcome mechanisms involved in development of resistance 
to GEM treatment. To the best of our knowledge our study is the first demonstration that 
inhibition of GPR55 not only reduces cancer progression in a well-established transgenic 
model but it also represents a therapeutically valid strategy. In this respect, this study provides 
the first validation of GPR55 as a novel target for cancer treatment likely to be able to improve 
patients’ outcome significantly.  
The importance and clinical relevance of these results are further highlighted by the 
observation that they were obtained in a model of PDAC, one of the deadliest cancer types 
and in urgent need of novel treatment options. The very few therapeutic options currently 
available for advanced PDAC solely increase survival by few months leaving the five years 
survival rate at a mere 5%. Development of drug resistance is one of the main reasons for 
such an abysmal prognosis. Our demonstration that combination of CBD and GEM can 
oppose mechanisms associated with drug resistance and increase survival of KPC mice is 
very important considering that both drugs are already approved for medical use and therefore 
this combination can be quickly tested in clinical trials.  
In conclusion, our study identified GPR55 as a novel critical mediator of PDAC 
development and progression. The demonstration that GPR55 is negatively regulated by p53 
and it controls cell cycle progression and growth of pancreatic cancer cells provides novel 
information into the mechanisms by which TP53 mutations can lead to PDAC development. 
Moreover, our study provides the first evidence that GPR55 is a therapeutically valid target 
whose inhibition, in particular in combination with GEM, results in improved survival in the 
transgenic model closest to the human disease currently available. These results represent a 
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huge step forward towards the identification of a novel treatment regime that could highly 
benefit PDAC patients. 
 
MATERIALS AND METHODS 
Mouse strains  
All animal experiments were conducted in compliance with institutional and national 
guidelines. Mice were housed in ventilated cages under standardized conditions (21°C, 60% 
humidity, 12-hour light/12-hour dark cycle, 20 changes air/hour), palpated daily and culled by 
carbon dioxide-mediated asphyxiation or cervical dislocation. KRASWT/G12D/TP53WT/R172H/Pdx1-
Cre+/+ (KPC), KRASWT/G12D/Pdx1-Cre+/+ (KC) and Pdx1-Cre+/+ mice were kindly provided by 
Prof. David A. Tuveson (Cancer Center at Cold Spring Harbor Laboratory). GPR55-/- mice 
were kindly provided by Prof. David Baker (Queen Mary University of London). GPR55-/- mice 
and KPC control mice were maintained on a GPR55 background. Mice were ear marked and 
specimen genotyped via DNA extraction and PCR (out sourced to Transnetyx Inc.). KPC mice 
used for drug treatments were maintained on a mixed C57BL/6,129Sv1 background. KPC 
mice were treated with CBD (GW Pharmaceuticals, 100mg/kg), GEM (100mg/kg), and with a 
combination of the two treatments. Mice enrolment was based on tumour size, measured by 
palpation. Specifically, mice underwent palpation every 24 h once they reached 80 days of 
age (predicted age when tumours should start to develop). Mice were assigned to the four 
arms (vehicle, CBD, GEM, CBD+GEM) by simple randomisation using a shuffled deck of cards 
as described.36 Vehicle and CBD were administered by daily intraperitoneal injection while 
GEM was administered by intraperitoneal injection every three days. Mice were checked daily 
and left until death or culled when pre-assigned end points were reached. The pre-assigned 
end points included mice displaying one of the following: development of abdominal ascites, 
severe cachexia, significant weight loss (approaching 20% of initial weight), extreme 
weakness, inactivity, discomfort or pain. No major side/adverse effects and no weight loss 





Mouse pancreatic tissues were placed in 10% neutral-buffered formalin immediately after 
sacrifice and incubated for at least 24 h. After embedding and sectioning procedures, tissues 
were stained with Hematoxylin and Eosin (H&E) to confirm the presence of tumours. Antibody 
staining was performed on 5 μm thick sections with the following antibodies and dilutions: 
GPR55 (1M urea buffer; dilution 1:100, 1:800; Novus Biologicals); pERKT202/Y204 (pH 6.0; 
dilution 1:75; Cell Signaling Technology); pS6S235/236 (pH 9.0; dilution 1:100; Cell Signaling 
Technology); RRM1 (pH 6.0; dilution 1:250; Abcam); Ki67 (pH 6.0; dilution 1:75; eBioscience). 
Representative images of antibody optimisation are shown in Supplementary Table 3. IHC 
slides were scored independently by two pathologists (RL and MP) blind to molecular data. 
The normal pancreatic tissue presented in Figure 1a was obtained from a patient without any 
findings of pancreatic cancer. 
 
Tissue microarray (TMA)  
Archived formalin-fixed, paraffin-embedded blocks from 54 patients diagnosed with primary 
PDAC were retrieved at the “Regina Elena” National Cancer Institute (Rome, Italy). TMA were 
constructed by removing 2-mm diameter cores of histologically confirmed tumor areas. TMA 
sections were then incubated with anti-GPR55 rabbit polyclonal antibody (dilution 1:100, 
incubation overnight, Novus Biologicals) after antigen retrieval by microwave treatment at 750 
W for 10 min in 1M urea buffer. Anti-rabbit EnVision kit (K4003, Dako, Glostrup, Denmark) 
was used for signal amplification. In control sections, the primary antibody was replaced with 
isotype-matched immunoglobulins. The expression of markers was quantified as percent of 





All sample sizes were chosen based prior studies performed in our laboratories and 
appropriate power calculations performed by expert biostatisticians of the School of Public 
Health at Curtin University. Unless otherwise specified Student’s t-Test (one sided) was used 
to determine statistical significance. In each case: *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
 
Additional Materials and Methods are in Supplementary Information  
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Figure 1. Genetic disruption of Gpr55 reduces PDAC growth in vivo. (a) Representative 
images of GPR55 protein expression in human normal pancreas, PDAC, and PDX tissues 
assessed by IHC. Scale bar: 50µm. Blue dotted lines indicate Islet of Langerhans, red dotted 
line indicates normal pancreatic duct. (b) Kaplan-Meier survival curves of KPC (n=18) and 
KPCG (n=21) mice. Logrank (Mantel-Cox) test p=0.0013, Gehan-Breslow-Wilcoxon test 
p=0.0032. Representative H&E staining of tissues from KPC and KPCG mice confirms 
presence of PDAC. Scale bar: 250µm. (c) Representative images of Ki67 protein expression 
in tissues from KPC and KPCG at the indicated stages of PanIN progression. Scale bar: 50µm. 
Graphs indicate the percentage of PanIN cells showing Ki67 staining. *p<0.05. 
Figure 2. In vitro and in vivo effects of GPR55 downregulation. (a,b) The indicated PDAC cell 
lines were transfected with a non-targeting siRNA (siControl) or siRNAs specifically targeting 
GPR55 and plated on soft agar as described in the Materials and Methods. Colonies were 
allowed to grow for 3-4 weeks. Data are means ± s.e.m. of n=3 independent experiments 
performed in duplicate. *p<0.05, **p<0.01 vs siControl. (c,d) Representative images of PDAC 
specimens from KPC and KPCG mice stained with antibodies recognising phosphorylated 
ERKT202/Y204 (c) and S6S235/236 (d). Scale bar: 50µm. Graphs indicate the percentage of PDAC 
cells showing positive staining for each antibody. *p<0.05. 
Figure 3. p53 regulates GPR55 protein levels in PDAC. (a) Kaplan-Meier survival curves of 
KC (n=19) and KCG (n=12) mice. Log-rank (Mantel-Cox) test p=0.17198, Gehan-Breslow-
Wilcoxon test p=0.9677. Representative images of H&E staining confirm presence of tumours. 
Scale bar: 250µm. (b) Pancreatic cancer cells SW1990, expressing wild type p53, were 
transfected with siRNAs targeting p53 or siControl and lysed after 48h. Representative 
Western blot and results from densitometry analysis are shown. Actinin was used as loading 
control. Data are means ± s.e.m. of n=3 independent experiments and are expressed as fold 
change of normalised GPR55 levels in cells transfected with siControl. *p<0.05. (c) Luciferase 
activity assays were performed in ASPC1 co-transfected with the indicated plasmids as 
specified in the Materials and Methods. Results are means ± s.e.m. of n=5 independent 
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experiments. *p<0.05. (d) The effect of re-introduction of miR34b-3p in ASPC1 and HPAFII 
cells on GPR55 protein expression was assessed by Western blot. Vinculin was used as 
loading control. Data from densitometry analysis are expressed as fold change of normalised 
GPR55 levels in cells transfected with miR control and are means ± s.e.m. of n=3 independent 
experiments. *p<0.05, **p<0.01. (e) Proposed model of p53/GPR55 signalling. Wild type, 
active p53 negatively regulates GPR55 protein expression by increasing miR34b-3p levels. 
The reduced GPR55 protein levels result in a weak proliferative signal. Mutated p53 is not 
able to regulate miR34b-3p levels and therefore GPR55 protein expression is not affected. 
High GPR55 protein expression results in a strong proliferative signal. Dotted arrows indicate 
inhibition; solid arrows indicate activation. 
Figure 4. Pharmacological inhibition of GPR55 inhibits cell cycle progression and MAPK 
signalling pathways. HPAFII (a) and PANC1 (b) cells were treated for 72h with the indicated 
concentrations of CBD or vehicle alone (“untreated”) in DMEM containing 10% FBS. Cell cycle 
analysis was performed by FACS. Results are expressed as percentage of cells in each phase 
of the cycle and are means ± s.e.m. of n=3 independent experiments. *p<0.05, **p<0.01. (c) 
HPAFII cells were treated with the indicated concentrations of CBD for 70h before incubation 
with 10μM EdU for further 2h. Graph indicates the percentage of cells that had incorporated 
EdU. Data are expressed as fold change of cells treated with vehicle (“untreated”) and are 
means ± s.e.m. of n=3 independent experiments performed in duplicate. **p<0.01, ***p<0.001. 
(d) Effect of CBD treatment on the cell cycle regulators Cyclin D1 and pRBS795. Total levels of 
RB were also assessed. Tubulin was used as loading control. (e) Effect of CBD treatment on 
activation and total levels of the indicated members of the MAPK/ERK signalling pathway. 
Tubulin or vinculin were used as loading controls. Results from densitometry analysis are 
expressed as fold change of normalised results from cells incubated with vehicle (“untreated”) 
and are means ± s.e.m. of n=3 independent experiments apart from: pERKT202/Y204 (n=7-9), 
pS6S235/236 (n=6), pRBS795 and RB (n=4). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
Figure 5. Pharmacological inhibition of GPR55 inhibits anchorage-independent growth of 
PDAC cells and potentiates the effect of GEM in vivo. (a,b) Effect of CDB and CID on 
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anchorage-independent growth of ASPC1 (a) and HPAFII (b) cells. Colonies were allowed to 
grow for 3-4 weeks. Control cells were incubated with the corresponding amount of vehicle 
(“untreated”). Data are means ± s.e.m. of n=3 independent experiments performed in 
duplicate. *p<0.05, **p<0.01 vs control cells. (c) Kaplan-Meier survival curves of KPC mice 
given the vehicle (n=9), CBD (n=10), GEM (n=8), and CBD plus GEM (n=7). Curves indicate 
days after start of each treatment. Logrank (Mantel-Cox) test p=0.0059, Logrank test for trend 
p=0.0007, Gehan-Breslow-Wilcoxon test p=0.0268. Images show representative H&E staining 
confirming the presence of tumours. Scale bar: 250µm. (d) Representative images of Ki67 
protein expression in PDAC specimens from each group of mice. Scale bar: 50µm. Graph 
indicates the percentage of PDAC cells showing Ki67 staining. *p<0.05. 
Figure 6. Effect of drugs combination on MAPK signalling pathway in vitro and in vivo. (a,b) 
Representative images of PDAC specimens from KPC mice given the indicated drugs, stained 
with antibodies recognising pERKT202/Y204 (a) and pS6S235/236 (b). Scale bar: 50µm. Graphs 
indicate the percentage of PDAC cells showing positive staining for each antibody. *p<0.05. 
(c) HPAFII cells were incubated in DMEM containing 10% FBS supplemented with 10µM CBD 
or 20nM GEM alone or in combination for 48h. Phosphorylation of ERKT202/Y204 and H2AX and 
levels of ERK were assessed by Western blotting analysis. Vinculin was used as loading 
control. Data from densitometry analysis are expressed as fold change of normalised results 
from cells incubated with vehicle (“untreated”) and are means ± s.e.m. of n=3 independent 
experiments. *p<0.05. 
Figure 7. Effect of GPR55 disruption and pharmacological treatment on ribonucleotide 
reductase levels. (a) HPAFII cells were transfected with the indicated siRNAs or transfection 
reagent (“untreated”) and lysed after 72h. Levels of RRM1 were assessed by Western blotting. 
Data from densitometry analysis are expressed as fold change of normalised results from cells 
transfected with siControl and are means ± s.e.m. of n=3 independent experiments. *p<0.05. 
(b) HPAFII cells were treated with the indicated concentrations of CBD for 24h or 72h and 
levels of RRM1 and RRM2 were assessed by Western blotting. Tubulin or vinculin were used 
as loading controls. Data from densitometry analysis are expressed as fold change of 
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normalised results from cells incubated with vehicle (“untreated”) and are means ± s.e.m. of 
n=3 independent experiments apart from RRM2 at 24h (n=4). *p<0.05, **p<0.01. (c,d) 
Representative images of PDAC specimens from KPC and KPCG mice (c) or KPC mice given 
CBD and GEM (d) stained with anti-RRM1 antibody. Scale bar: 50µm. Graph indicates the 
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Supplementary Materials and Methods 
 
Cell culture and transfection 
All cell lines were obtained from American Type Culture Collection (ATCC) apart from the 
immortalised normal pancreatic cell line HPDE, kindly provided by Prof Hemant Kocher 
(Queen Mary University of London). Cell lines were authenticated and routinely tested for 
mycoplasma contamination. All cell lines (apart from HPDE) were cultured in DMEM 
supplemented with 10% (v/v) fetal bovine serum (FBS), 1X penicillin/streptomycin and 
glutamine, and 1% (v/v) sodium pyruvate. HPDE cells were cultured in keratinocyte serum-
free medium supplemented with epidermal growth factor and bovine pituitary extract. Cells 
were maintained under standard cell culture conditions (37°C, 20% O2, 5% CO2). siRNAs were 
transfected using Oligofectamine™ or Lipofectamine® RNAiMAX, according to the 
manufacturer’s instructions. 
 
Cell growth assays  
For cell counting, cells were seeded in 12 well plates and grown in cell culture medium 
supplemented with 10% FBS for the indicated times. When necessary, cells were treated with 
the GPR55 antagonists CBD or CID16020046 (Tocris Bioscience). The number of cells was 
assessed after 72 h by cell counting. For anchorage-independent growth, 1.2% agarose gel 
was melted and then placed in a water bath at 55°C. DMEM medium was supplemented with 
20% (v/v) FBS, 2X penicillin/streptomycin and glutamine and 2% (v/v) sodium pyruvate (2X 
DMEM), and kept at 37°C. A mix of 1.2% melted agarose gel and 2X DMEM was used to 
generate 2ml 0.6% agarose thick base layer. The mix was poured into one well of a 6-well 
plate and left to solidify. Where indicated, cells were transfected for 24 h. Cells were washed, 
detached, counted and a suspension of 20,000 cells was prepared in 1.5ml of 2X DMEM. 
Then 0.75ml of 1.2% agarose gel and 0.75ml of 2X DMEM was mixed to form a 0.3% agarose 
gel. The mix was poured on top of the solidified 0.6% agarose gel. 2ml of DMEM was added 
on top and cells were left to grow at 37°C in a 5% CO2 atmosphere. Colonies were fixed with 
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4% paraformaldehyde or methanol/acetic acid in PBS 3-4 weeks after plating, stained with 
Crystal Violet (0.05%) and counted under the microscope or using the ChemiDoc XRS+ 
System (Bio-Rad).  
 
Cell cycle analysis  
Cells were seeded in a 6 well plate (200,000 cells/well) and transfected with the indicated 
siRNAs or treated with CBD. At indicated times, cells were washed once with PBS, detached 
and collected in 1.5ml microfuge tubes and centrifuged at 1,200 rpm for 5 min. Pelleted cells 
were then fixed in ice-cold 70% ethanol by adding one drop at a time on a vortex and left at 
4°C from 60 min to a week. Cells were then washed and centrifuged at 1,200 rpm for 5 min 
and re-suspended in 200μl Vindellövs Propidium Iodide (PI) solution (50μg/ml PI, 
Ribonuclease I 100μg/ml) before being analysed by FACS, collecting 50,000 events per 
sample. 
EdU assay. To assess EdU incorporation, cells were treated with 5μM or 10μM of CBD for 70 
h and then treated with 10µM EdU for 2 h. Cells were fixed in 70% ethanol for 1 h and then 
treated according to the manufacturer’s instructions (Thermo Fisher Scientific). Cells were 
washed and centrifuged at 1,200 rpm for 5 min and resuspended in 500μl Vindellövs PI 
solution before being analysed by flow cytometry, collecting 50,000 events per sample using 
FACS Diva software. 
 
Apoptosis assays  
For the Annexin V assay, cells were plated in 6 well plates (200,000 cells/well) and transfected 
with the indicated siRNAs. At 48 h post transfection, cells were collected (including the 
supernatant) and pelleted. The pellet was resuspended in 400µl 1X Annexin V Binding Buffer 
and 2µl of Annexin V-FITC and incubated in the dark for 15 min at room temperature. Then, 
4µl PI was added and the samples were analysed using FACS Diva software, collecting 
20,000 events per sample. A control of unstained cells was incubated with 1X Annexin V 
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Binding Buffer alone and Annexin V-FITC or PI in order to set the quadrants. Caspase 3 
activity was measured by using an EnzCheck® Caspase 3 Assay Kit #2 (Cat. No E-13184, 
Molecular Probes®, Life Technologies) according to manufacturer’s instructions. Cells were 
plated in 6 well plates (200,000 cells/well) and transfected with indicated siRNAs. At 48 h 
post transfection, cells were washed once with PBS and pelleted. The pellets were then 
resuspended in 100µl 1X cell lysis buffer solution and kept on ice for 30 min. Cell lysates 
were then centrifuged at 5,000 rpm for 5 min and the supernatant was transferred to a new 
1.5ml microfuge tube. 1X cell lysis buffer was used as a control to determine background 
fluorescence of the substrate. 50µl of 2X substrate working solution was added in each 
sample and control and 100µl were transferred in a 96 well plate and incubated for 75 min 
at room temperature. Fluorescence was then measured using a spectrophotometer 
(Synergy HT) at excitation/emission 496/520nm. The protein concentration of each sample 
was determined using the Bradford or BCA protein assay. Fluorescence results were then 
normalised according to the protein concentration of each sample. 
 
RT-qPCR analysis  
RNA was extracted from cells or murine tissues using the GeneJET RNA Purification Kit 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. The complementary 
DNA (cDNA) synthesis was performed on ice using Maxima Reverse Transcriptase (Thermo 
Fisher Scientific) according to the manufacturer’s instructions. RT-qPCR was performed using 
2X Maxima SYBR green/Fluorescein (Fermentas) qPCR mix and the ABI 7500 RT-QPCR. 
QARS, GAPDH or RPS14 cDNA were also amplified as housekeeping gene controls. All 
experiments were performed in triplicate. Quantification of the relative changes in gene 
expression was calculated using the relative ddCT analysis mode of the ABI 7500 Real-Time 
PCR system software. GAPDH forward and reverse primers 5’-
AGGGCTGCTTTTAACTCTGGT-3’, 5’-CCCCACTTGATTTTGGAGGGA-3’; GPR55 forward 
and reverse primers 5’-GTTTCCATGGGAAAGTGGAA-3’, 5’-
GGAAGGAGACCACGAAGACA-3’; QARS forward and reverse primers 5’-
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CAGGGGTCTGGCTTATGTGT-3’ 5’-CTCTGAAAACTTGCCCTTGC-3’. RRM1 forward and 
reverse primers 5’-ACTAAGCACCCTGACTATGCTATCC-3’ 5’-




Cells were washed and lysed either in 2% SDS or in ice-cold lysis buffer [50 mM Tris, pH 7.5, 
150mM NaCl, 1% Triton X-100, 2mM EDTA, 2mM EGTA, 1μl/ml Protease inhibitor cocktail 
(Sigma Aldrich), 1μl/ml Phosphatase inhibitor cocktail A (Sigma Aldrich) and 1μl/ml 
Phosphatase inhibitor cocktail B (Sigma Aldrich)]. Samples were separated by SDS-PAGE 
and transferred to nitrocellulose membranes. Membranes were then incubated in PBS 
supplemented with 0.05% (v/v) Tween 20 (PBS-T) containing 5% skim milk powder for 1 h at 
room temperature, followed by overnight incubation with primary antibodies at 4°C. After 
washing with PBS-T, membranes were incubated with secondary antibodies for 1 h at room 
temperature, washed with PBS-T and exposed to ECL reagent. Anti-p53 (1:1000, Cell 
Signaling Technology, product code 2527); anti-Tubulin (1:10000, Sigma-Aldrich, product 
code T9026); anti-pERKT202/Y204 (1:2000, Cell Signaling Technology, product code 4370); anti-
pS6S235/236 (1:1000, Cell Signaling Technology, product code 4858); anti-pMEKS217/221 (1:1000, 
Cell Signaling Technology, product code 9154); anti-p90RSKS380 (1:1000, Cell Signaling 
Technology, product code 11989);  anti-RRM1 (1:1000, Santa Cruz Biotechnology, product 
code sc-11733); anti-RRM2 (1:1000, Santa Cruz Biotechnology, product code sc-10846); anti-
Vinculin (1:1000, Cell Signaling Technology, product code 4650); anti cyclin D1 (1:1000, Cell 
Signaling Technology, product code 2978); anti ERK2 (1:1000, Santa Cruz Biotechnology, 
product code sc-154); anti RSK1/RSK2/RSK3 (1:1000, Cell Signaling Technology, product 
code 9355); anti MEK1/2 (1:1000, Cell Signaling Technology, product code 4694); anti S6 
(1:1000, Cell Signaling Technology, product code 2317); anti actinin (1:1000, Cell Signaling 
Technology, product code 3134). For GPR55 staining, membranes were incubated in TBS 
containing 0.05% Tween (TBS-T) supplemented with 3% BSA for 1 h before overnight 
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incubation with anti-GPR55 (1:80,000, Cayman Chemical, product code 10224). Densitometry 
analysis was performed using Image J. In all graphs, specific band densities were normalised 
to the corresponding loading control.  
 
microRNA (miR) analysis  
To assess miR levels, cells were washed twice with PBS and lysed using Qiazol Lysis Reagent 
(Qiagen). Total RNA was extracted using miRNAs Mini Kit (Qiagen), and cDNA synthesised 
using TaqMan® MicroRNA Reverse Transcription kit (Life Technologies) according to the 
manufacturer’s instructions. PCR was performed according to the manufacturer’s instructions 
(TaqMan® MicroRNA Assays Protocol, Life Technologies). Analysis of miR expression was 
performed using the cycle threshold (Ct) and RNU48 as endogenous control. Levels of miRs 
were obtained using the ∆∆Ct method and expressed as 2(-∆∆Ct) values.  
 
Luciferase assay 
Plasmids encoding the luciferase gene either under the control of the 3’-UTR of the GPR55 
(defined as “GPR55” in Figure 3c) or without a regulatory region (defined as “Control” in Figure 
3c) were used. Both plasmids were purchased from ABM®. ASPC1 cells were plated in a 24 
well plate and transiently co-transfected with each 3’-UTR plasmid in combination with an 
empty vector (pcDNA) or a plasmid encoding either wild type (wt) or p53 mutants (p53 143Ala, 
p53 175His). This led to two groups of transfected cells: a) cells co-transfected with “Control” 
and either pcDNA or p53 wt or p53 mutants; b) cells co-transfected with “GPR55” and either 
pcDNA or p53 wt or p53 mutants. Assays were performed by using the Luciferase assay 
system (Promega, cat number E1500) according to the manufacturer’s instructions. For each 
group of transfections (a & b), results were expressed as fold change of normalised luciferase 
activity in cells co-transfected with pcDNA. To obtain final results, values for group b were 
expressed as fold change of corresponding values in group a. Plasmids encoding p53 carrying 
gain-of-function mutations at positions 143Ala or 175His were kindly provided by Dr Massimo 




Human phospho-kinase array  
HPAFII cells were treated with 10µM CBD or vehicle alone in DMEM containing 10% FBS for 
24h before being lysed. Analysis of the phosphorylation status of several kinases was 
performed using Proteome Profiler Human Phospho-Kinase Array Kit (Cat. No. ARY003B, 
R&D Systems, Abingdon, UK) according to the manufacturer’s instructions. Densitometry 






Supplementary Figure legends 
 
Supplementary Figure 1. GPR55 expression in PDAC. (a) Representative Western blot of 
GPR55 protein expression in a panel of PDAC cell lines. Tubulin was used as loading control. 
All cell lines in figure harbour TP53 mutations. (b) Representative IHC images of GPR55 
protein expression in pancreas from Pdx1-Cre+/+ mice as well as images of non-neoplastic 
pancreas and PDAC tissues from KPC mice. Images of non-neoplastic pancreas and PDAC 
tissues from KPCG mice incubated with the anti GPR55 antibody are also shown. Blue dotted 
lines indicate Islet of Langerhans, red dotted lines indicate normal pancreatic duct. Scale bar: 
50µm. 
 
Supplementary Figure 2. Effect of GPR55 downregulation on PDAC cell growth. ASPC1 
(a,b), HPAFII (c,d), and PANC1 (e,f) were transfected with a non-targeting siRNA (siControl), 
siRNAs specifically targeting GPR55 or transfection reagent alone (“untreated”). In a, c and e 
the number of cells was assessed at 72 h post transfection by manual counting as described 
in the Materials and Methods section. Data are expressed as fold change of untreated cells 
and are means ± s.e.m. of n=3 independent experiments performed in duplicate. *p<0.05, 
**p<0.01, ***p<0.001 vs untreated cells. (b,d,f) Representative RT-qPCR of GPR55 mRNA 
levels in cells transfected with the indicated siRNAs at 72 h post transfection. QARS was used 
as a housekeeping gene. Data are expressed as fold change of cells transfected with siControl 
and are means ± s.e.m. of n=3 independent experiments performed in duplicate. *p<0.05, 
**p<0.01, ***p<0.001 vs cells transfected with siControl. 
 
Supplementary Figure 3. GPR55 regulation of PDAC cell cycle and MAPK/ERK signalling 
pathways. (a,b) Effect of GPR55 downregulation on HPAFII (a) and PANC1 (b) cell cycle. Cell 
cycle analysis was performed by FACS at 48 h after transfection. Cells were grown in DMEM 
containing 10% FBS. Results are expressed as percentage of cells in each phase of the cycle 
and are means ± s.e.m. of n=3 independent experiments. *p<0.05, **p<0.01, ***p<0.001 vs 
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cells transfected with siControl. (c) Effect of GPR55 downregulation on Cyclin D1, Cyclin D2, 
and Cyclin B1 mRNA levels assessed by RT-qPCR. GAPDH was used as a housekeeping 
gene. Results are expressed as fold change of cells transfected with siControl and are means 
± s.e.m. of n=3 independent experiments. *p<0.05; **p<0.01. (d) ASPC1 cells were 
transfected with the indicated siRNAs or transfection reagent alone (“untreated”) and the 
activity of caspase 3 was assessed at 48 h post transfection. Data are expressed as fold 
change of caspase 3 activation in untreated cells and are means ± s.e.m. of n=2 independent 
experiments. (e) HPAFII cells were transfected with the indicated siRNAs or transfection 
reagent alone (“untreated”) and analysed at 48 h post transfection by Annexin V/FACS 
analysis as described in the Materials and Methods section. Results indicate the percentage 
of apoptotic cells (early and late apoptotic cells) and are means ± s.e.m. of n=2 independent 
experiments. (f) Effect of GPR55 downregulation on pERKT202/Y204 and pS6S235/236 and total 
ERK and S6 levels, assessed by Western blotting analysis. Tubulin and vinculin were used as 
loading controls. Data from densitometry analysis are expressed as fold change of normalised 
results from cells transfected with siControl and are means ± s.e.m. of n=3 independent 
experiments. *p<0.05, **p<0.01. 
 
Supplementary Figure 4. p53 regulates GPR55 through miR regulation. (a) Western blotting 
analysis of GPR55 protein expression in PDAC murine cell lines derived from the indicated 
mouse models. Tubulin was used as loading control. Data from densitometry analysis are 
expressed as fold change of normalised levels of GPR55 in PZR1 cells and are means ± 
s.e.m. of n=3 independent experiments. *p<0.05, **p<0.01. (b) ASPC1 cells were transfected 
with a plasmid encoding wild type p53 or corresponding empty vector (pcDNA). Levels of 
GPR55 were assessed by Western blotting analysis. Tubulin was used as loading control. 
Data from densitometry analysis are expressed as fold change of normalised levels of GPR55 
in cells transfected with pcDNA and are means ± s.e.m. of n=3 independent experiments. 
*p<0.05. (c) HEK293T cells, expressing wild type p53, were transfected with two siRNAs 
specifically targeting p53 and a non-targeting siRNA (siControl). Cells were lysed after 48 h 
42 
 
and levels of GPR55 and p53 were assessed by Western blotting analysis. Actinin was used 
as loading control. Representative blot and results from densitometry analysis are shown. 
Data are means ± s.e.m. of n=3 independent experiments and are expressed as fold change 
of GPR55 levels normalised to loading control in cells transfected with siControl. *p<0.05, 
**p<0.01. (d) ASPC1 cells were transfected with plasmids expressing the luciferase gene 
under the control of the 3'-UTR of GPR55 (“GPR55”) or the luciferase gene without 
regulatory regions (“Control”) in combination with pcDNA or plasmids encoding wild type or 
the indicated mutants p53. Expression levels of the exogenous proteins were assessed by 
Western blotting analysis. Tubulin was used as loading control. (e) In silico analysis of 3’-UTR 
GPR55 binding site showing matching sequences with hsa-miR34b-3p. (f) Levels of miR34b-
3p in HPDE, ASPC1 and HPAFII cells assessed by RT-qPCR. n=2. (g) ASPC1 cells were 
transfected with a plasmid encoding wild type p53 or empty vector. At the indicated times, 
levels of miR34b-3p were assessed by RT-qPCR. 
 
Supplementary Figure 5. Effect of pharmacological inhibition of GPR55 on PDAC cell growth. 
ASPC1 (a), HPAFII (b), BXPC3 (c) and PANC1 (d) cells were treated with the indicated 
concentrations of drugs in DMEM containing 10% FBS. The number of viable cells was 
assessed after 72 h by manual counting. Control cells were incubated with the corresponding 
amount of vehicle (“untreated”). Data are expressed as fold change of control cells and are 
means ± s.e.m. of n=3 independent experiments performed in duplicate. *p<0.05, ** p<0.01, 
*** p<0.001 vs control cells.  
 
Supplementary Figure 6. Effect of CBD on a panel of kinases and related proteins. Results 
from densitometry analysis of the phospho-kinase array assay performed in HPAFII treated 
with 10µM CBD or incubated with vehicle alone (untreated). For each protein data show values 
from CBD-treated sample expressed as fold change compared to the corresponding value 




Supplementary Figure 7. Effect of combination of pharmacological inhibition of GPR55 and 
GEM on PDAC cell growth. HPAFII (a) and PANC1 (b) cells were treated with the indicated 
concentrations of drugs alone or in combination in DMEM containing 10% FBS and the 
number of cells was assessed after 72 h. Control cells were incubated with the corresponding 
amount of vehicle (“untreated”). Data are expressed as fold change of control cells and are 
means ± s.e.m. of n=3 (a) and n=4 (b) independent experiments performed in duplicate.  
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
 
Supplementary Figure 8. Effect of GPR55 inhibition and ablation on RRM1 mRNA levels. (a) 
HPAFII cells were treated with 10µM CBD for 48h or incubated with vehicle, DMSO, alone 
(untreated). Effect on RRM1 mRNA levels was assessed by RT-qPCR. GAPDH was used as 
housekeeping gene. Results are expressed as fold change of levels in untreated cells and are 
means ± s.e.m. of n=3 independent experiments. **p<0.01. (b) RNA was extracted from 
pancreata from KPC (n=5) and KPCG (n=6) mice and the levels of RRM1 mRNA were 
assessed by RT-qPCR. RPS14 was used as housekeeping gene. **p<0.01. 
 
Supplementary Table 1. miR34 family members that are predicted to target GPR55.  
 
Supplementary Table 2. Values of combination index (CI) and dose reduction index (DRI) for 
the indicated combinations as assessed by CompuSyn software. CI<1, CI=1, CI>1 indicate 
synergism, additivity and antagonism respectively. 
 

























































Supplementary Table 3 
 
 
